For better or for worse and, more to the point, for richer or for poorer, biotech companies conduct their clinical trials in a fishbowl. Which is why it behooves companies to take a proactive role in explaining and clarifying data and clinical development plans.

This is particularly true in cases where the data aren't simple to interpret at first glance, as was the case with Alpha-Beta Technology Inc.'s presentation of its second Phase I/II study of Betafectin in high-risk surgery patients at the Surgical Infection Society meeting on April 29.